Tenet

Tenet Medicines is a clinical-stage biotechnology company focused on developing innovative therapies for rare metabolic diseases, specifically targeting bone mineralization disorders. The company's lead program, TN-101, is a second-generation recombinant alkaline phosphatase enzyme replacement therapy currently in Phase 2 development for the treatment of hypophosphatasia (HPP) in adults. Founded by a team of experienced rare disease drug developers, Tenet was acquired by Alexion, AstraZeneca's rare disease unit, in April 2024. The acquisition strengthens Alexion's leadership in the HPP space by adding a potential next-generation treatment to its existing portfolio. Tenet's approach leverages advanced protein engineering to improve upon first-generation therapies, aiming for better efficacy and patient convenience.